Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 24, 2026
TickeronGET DAILY SIGNALS
HUM vs UNH: Medicare Momentum Meets Diversified Stability in Managed Care

HUM vs UNH: Medicare Momentum Meets Diversified Stability in Managed Care

Key Takeaways

  • HUM has shown sharper recent momentum, supported by a strong recovery in its Medicare Advantage Star Ratings, though it carries a higher valuation and greater concentration risk.
  • UNH provides broader diversification across insurance and healthcare services, with a steadier multi-quarter earnings recovery and a consistent dividend history.
  • Both companies face elevated medical costs, yet each has demonstrated improving medical cost ratios in recent quarters.
  • HUM remains closely tied to government-funded Medicare policy, while UNH spans commercial, Medicare, Medicaid, and pharmacy services, which reduces reliance on any single program.
  • Recent relative performance has favored HUM, whereas UNH has offered greater stability and trades at a lower valuation multiple.
  • For additional context, review HUM Major News and HUM Today's Price Move, along with UNH Major News and UNH Today's Price Move.
  • To observe how automated strategies are currently positioned, explore Trending AI Robots.

Why Compare HUM and UNH Now

Humana (HUM) and UnitedHealth Group (UNH) stand out as leading names in U.S. managed care, yet they offer distinct exposures within the sector. HUM focuses primarily on Medicare Advantage for seniors, while UNH combines insurance operations with the diversified Optum platform. This comparison helps investors evaluate concentrated growth potential against broader stability, especially as medical cost trends and regulatory shifts influence performance.

HUM’s Recent Momentum and Key Drivers

HUM derives most revenue from Medicare Advantage plans, complemented by its CenterWell care-delivery segment. A notable regulatory development came with the 2027 Medicare Advantage Star Ratings, where roughly 95% of members are now in plans rated four stars or higher, up from about 20% previously. This improvement has supported a meaningful share-price recovery after a period of pressure. The company has also made progress on margins, with the insurance benefit ratio moving below the 90% target in recent quarters, while CenterWell revenues expanded at a double-digit rate. That said, HUM stays sensitive to Medicare reimbursement policy and medical cost trends, which can add to volatility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

UNH’s Steady Recovery and Diversified Base

UNH runs the largest U.S. health insurer alongside the Optum platform, which includes care delivery, pharmacy services, and health technology. Under current leadership, management has focused on exiting lower-margin areas to improve profitability. This approach has delivered several consecutive quarters of earnings beats, supported by a better medical care ratio and wider operating margins, with full-year guidance raised multiple times. Diversification helps buffer segment-specific weakness, while a 17-year streak of dividend increases and a forward yield near 2.4% add defensive qualities. Trading has remained measured as investors assess whether margin gains can offset planned enrollment reductions.

Head-to-Head: Concentration Versus Diversification

The main distinction lies in focus versus breadth. HUM essentially represents a leveraged position on Medicare Advantage dynamics, where reimbursement rates, Star Ratings, and senior utilization drive results. This concentration amplifies both the recent rebound and potential downside. UNH, by blending insurance with pharmacy, care delivery, and technology, tends to produce smoother earnings across cycles but caps upside from any one catalyst.

On momentum, HUM has led in recent months due to the Star Ratings repricing. On stability and valuation, UNH holds an edge with a lower forward price-to-earnings multiple and reliable dividend. Growth paths differ as well: HUM emphasizes membership retention and CenterWell expansion, while UNH pursues margin-driven earnings growth alongside deliberate enrollment trimming. Regulatory and medical-cost risks appear more pronounced at HUM, whereas UNH appeals more to income-focused investors.

AI Perspective on the Two Names

From what I see in the data, Tickeron’s AI would likely lean toward UNH for its stronger trend consistency and diversified profile. The pattern of earnings beats, repeated guidance increases, and improving medical cost ratio forms a more durable sequence than a single catalyst-driven move. HUM shows stronger near-term momentum from the Star Ratings improvement, yet its concentrated Medicare exposure and higher valuation introduce greater variability. In probabilistic terms, UNH may suit systematic strategies better, while HUM offers a higher-volatility expression of the sector theme.

Exploring Tickeron AI Trading Bots

In my own research process, I frequently review Tickeron’s Trending AI Robots to understand how automated strategies are currently positioned across the market. The page highlights bots from a large library that best align with prevailing conditions, covering a range of styles, timeframes, and performance metrics. This helps me compare discretionary ideas against data-driven alternatives without committing capital upfront.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HUM, UNH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


HUM's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for HUM moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 21 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUM as a result. In 47 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

The Moving Average Convergence Divergence Histogram (MACD) for HUM turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

HUM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 224 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

HUM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company offers health insurance coverage and related services

Industry ManagedHealthCare

Industry
Managed Health Care
Address
101 East Main Street
Phone
+1 502 580-1000
Employees
67060
Web
https://www.humana.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.